Clinical experiences with the use of indole-3-pyruvic acid.
In the last few years, Indol-3-pyruvic acid (IPA) has been subjected to 5 pilot clinical trials in volunteers and a phase II study on patients affected by anxiety, with or without sleep problems. Overall, results indicated a very good safety profile, relief from anxiety and a better quality of sleep in patients treated with IPA. Moreover, the drug showed no withdrawal signs, but positive effects on mood, improving feelings of relaxation, calmness and happiness. The mechanism of action of IPA, depending on increased turnover of some indoles in the CNS, appears clearly distinct from that of benzodiazepines, suggesting that the drug might be used in the treatment of symptoms of mild anxiety and stress experienced by busy and anxious people.
Politi
V
V
Polifarma Res. Centre, Rome, Italy.
De Luca
G
G
Gallai
V
V
Puca
Comin
M
M
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012893:Sleep Wake Disorders / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D007211:Indoles; C008122:indol-3-yl pyruvic acid